68Ga-pentixafor趋化因子受体4显像评估急性心肌梗死后炎性反应的研究现状

Current status of 68Ga-pentixafor imaging targeting chemokine receptor 4 in accessing inflammation after acute myocardial infarction

急性心肌梗死(AMI)后过度的炎性反应不利于梗死心肌的修复,在炎性反应高峰期进行抗炎干预有一定的疗效。因此,在体纵向监测AMI后梗死区的炎性反应演变,对实现个体化风险预测、指导抗炎治疗策略,进而改善预后具有重要意义。68Ga-pentixafor靶向细胞表面的趋化因子受体4(CXCR4),显像前无需特殊准备,可在体可视化梗死区的炎性反应强度、范围及演变,同时提供心外相关器官的摄取变化,是AMI后风险评估和治疗干预中颇具应用潜力的新型分子探针。该文就其示踪特性、研究现状、在AMI的相关应用探索及局限性等方面进行综述。

The excessive inflammatory response after acute myocardial infarction(AMI)is detrimental to the repair of the infarcted myocardium,and anti-inflammatory interventions at the peak of inflammation have shown efficacy.Therefore,longitudinal monitoring of myocardial inflammatory evolution after AMI in vivo is important for individualized risk prediction,anti-inflammatory treatment strategies guidance and further prognosis improvement.68Ga-pentixafor,a promising novel probe targeting C-X-C chemokine receptor 4(CXCR4)on the surface of inflammatory cells,with no special preparation before imaging,allows in vivo visualization of the inflammation intensity,extent and evolution in the infarcted myocardium as well as the response of other related extra-cardiac organs.This review referred to its radiopharmaceutical characteristics,research status,explorations and limitations in AMI.